APA (7th ed.) Citation

Z, Z., K, S., K, S., RA, B., JK, W., DC, K., . . . BC, C. (2024). Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on anti-PD-1 therapy. NPJ precision oncology, 8(1), 267. https://doi.org/10.1038/s41698-024-00759-8

Chicago Style (17th ed.) Citation

Z, Zhang, et al. "Methylation Cytometric Pretreatment Blood Immune Profiles with Tumor Mutation Burden as Prognostic Indicators for Survival Outcomes in Head and Neck Cancer Patients on Anti-PD-1 Therapy." NPJ Precision Oncology 8, no. 1 (2024): 267. https://doi.org/10.1038/s41698-024-00759-8.

MLA (9th ed.) Citation

Z, Zhang, et al. "Methylation Cytometric Pretreatment Blood Immune Profiles with Tumor Mutation Burden as Prognostic Indicators for Survival Outcomes in Head and Neck Cancer Patients on Anti-PD-1 Therapy." NPJ Precision Oncology, vol. 8, no. 1, 2024, p. 267, https://doi.org/10.1038/s41698-024-00759-8.